Login
$IMVT
$33.28 -$0.90 (2.63%) Live

$IMVT SEC Filings

Filed On Filing
12 Nov 2026 Form 4: Pande Atul, Director

Received 3,000 shares by exercise or conversion ($25.3K) · Sold 3,000 shares ($108K)

12 Nov 2026 144
09 Nov 2026 S-3ASR
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

DURHAM, N.C. November 9, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its second ...

30 Oct 2026 Form 4: Girao Tiago, Chief Financial Officer

Sold 6,606 shares ($188K)

23 Oct 2026 Form 4: Stout Jay S, Chief Technology Officer

Sold 2,595 shares ($75.1K)

09 Oct 2026 Form 4: Stout Jay S, Chief Technology Officer

Sold 3,809 shares ($122K)

09 Oct 2026 Form 4: Van Tuyl Christopher, Chief Legal Officer

Sold 1,327 shares ($42.5K)

09 Oct 2026 Form 4: Gloria Melanie, Chief Operating Officer

Sold 2,241 shares ($71.8K)

05 Oct 2026 Form 4: Venker Eric, Director

Received 92,187 shares by exercise or conversion ($1.33M) · Returned 85,886 shares to the issuer ($2.89M) · Sold 3,506 shares ($120K)

25 Sep 2026 Form 4: Van Tuyl Christopher, Chief Legal Officer

Sold 2,846 shares ($103K)

03 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 2, 2026, Immunovant, Inc. (“Immunovant”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). There were 198,373,370 shares of common stock and Series A preferred stock represented at the Annual Meeting by va...

28 Aug 2026 Form 4: Pande Atul, Director

Received 1,500 shares by exercise or conversion ($12.6K) · Sold 1,500 shares ($64.9K)

21 Aug 2026 Form 4: Gloria Melanie, Chief Operating Officer

Sold 3,056 shares ($135K)

14 Aug 2026 SCHEDULE 13G/A
06 Aug 2026 10-Q
06 Aug 2026 8-K: Results of Operations and Financial Condition

DURHAM, N.C. August 6, 2026 – Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its first fis...

24 Jul 2026 Form 4: Pande Atul, Director

Received 1,500 shares by exercise or conversion ($12.6K) · Sold 1,500 shares ($59.7K)

24 Jul 2026 Form 4: Girao Tiago, Chief Financial Officer

Sold 6,798 shares ($263K)

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support